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In the past decade, genome-wide association studies (GWAS) have successfully identiﬁed thousands of genetic
variants underlying susceptibility to complex diseases. However, the results from these studies often do not pro-
vide evidence on how the variants affect downstream pathways and lead to the disease. Therefore, in the post-
GWAS era the greatest challenge lies in combining GWAS ﬁndingswith additional molecular data to functionally
characterize the associations. The advances in various ~omics techniques havemade it possible to investigate the
effect of risk variants on intermediatemolecular levels, such as gene expression, methylation, protein abundance
ormetabolite levels. As disease aetiology is complex, no singlemolecular analysis is expected to fully unravel the
diseasemechanism.Multiplemolecular levels can interact and also showplasticity in different physiological con-
ditions, cell types anddisease stages. There is therefore a great need for new integrative approaches that can com-
bine data from different molecular levels and can help construct the causal inference from genotype to
phenotype. Systems genetics is such an approach; it is used to study genetic effectswithin the larger scope of sys-
tems biology by integrating genotype information with various ~omics datasets as well as with environmental
and physiological variables. In this review, we describe this approach and discuss how it can help us unravel
the molecular mechanisms through which genetic variation causes disease. This article is part of a Special Issue
entitled: From Genome to Function.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
Over the last 5–10 years enormous progress has beenmade in iden-
tifying genetic variants underlying various phenotypes, including differ-
ent complex diseases and complex traits. Genome-wide association
studies (GWAS), which aim to correlate allele frequencies of single nu-
cleotide polymorphisms (SNPs)with a disease status or trait variation in
a humanpopulation, have nowbecome a standard tool in human genet-
ics research [1]. At the moment (March 2014), 1818 GWAS papers
have been published describing 12,498 associations, as listed in the
GWAS catalogue of the National Human Genome Research Institutenome to Function.
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02114, USA. Tel.: +1 617 724(www.genome.gov/gwastudies/) [2]. And new loci are still being dis-
covered. From a medical perspective, the ultimate goal of GWAS is to
identify the causal variants of a phenotype, their functional effects and
the biological pathways throughwhich they operate in complex disease
pathogenesis. However, although thousands of phenotype-associated
loci have been identiﬁed, the molecular mechanisms through which
they act are still largely unknown. In practice, the interpretation of
GWAS ﬁndings is complicated by the fact that most identiﬁed associa-
tions are part of a larger region of correlated variants. SNPs in close
proximity can be in strong linkage disequilibriumwith each other, mak-
ing it hard to pinpoint the causal variant. Furthermore, the majority of
identiﬁed SNPs are annotated outside of protein-coding genes, indicat-
ing that the underlying mechanism is most likely regulatory. This
makes it more challenging to elucidate the direct functional conse-
quences of the variants.
The lack of explanatory power of GWAS thus calls for additional
methods to uncover the mechanisms that underlie complex diseases.
Over the last few years, different approaches have been explored to dis-
cover functional relationships between genes at the associated loci, for
instance, by searching for genes with similar functions or within the
same molecular pathway [3–5]. One widely used approach is the gene
set enrichment analysis, which determines whether an a priori deﬁned
set of genes is statistically enriched for disease associations. Many tools
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protein–protein interactions [8], information from pathway databases,
such as the Kyoto Encyclopaedia of Genes and Genomes (KEGG) [9,
10], or co-occurrence/co-citation in the literature [11]. Although these
methods have proven successful in prioritizing candidate genes and
identifying overrepresented pathways, they tend to be heavily biased
by the extent of prior knowledge available (including functional anno-
tation and curated information). Many disease-associated candidate
genes that lack prior biological pathway annotation, will unintentional-
ly ‘miss the mark’ using these annotation-based enrichment methods.
The past few decades have witnessed an enormous growth in the
quantity, quality, diversity and richness of human molecular and func-
tional data being generated. The advances in high-throughput technol-
ogies have enabled large-scale proﬁling of the transcriptome, proteome,
metabolome, epigenome and microbiome across multiple disease
states, phenotypes, perturbation conditions and/or cell types. These
~omics proﬁling approaches can be used not only to evaluate andmon-
itor the change of individual biomolecules in diseases, but also to inves-
tigate the genetic basis of inter-individual variation for the molecular
traits. Systems genetics, which evaluates this genetic basis, aims to re-
veal the genetic ﬂow from DNA to the phenotype through intermediate
molecular traits. This strategy has been proposed as a powerful method
to investigate themolecularmechanisms underlying complex traits and
diseases [12,13]. To do so, the experimental design and analysis frame-
work can include multiple steps (Fig. 1): 1) association studies or link-
age analysis to identify genetic loci that underlie complex traits and
diseases; 2) genomics analysis to proﬁle ~omics data and identify the
biomolecules that are of relevance; 3) genetical genomics studies to in-
vestigate the effect of genetic variants on multiple intermediateo
g
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Fig. 1. The systems genetics approach. Systems genetics combines genetical genomics, genetic a
notype. The approach integrates genotype information (g)with large-scale ~omics proﬁling dat
different relationships.molecular phenotypes and to illustrate the genetic variation of molecu-
lar traits; and 4) network modelling and causal inference analysis to
construct the molecular circuitry from genotype to phenotype. In this
review, we describe how systems genetics can help close the gap be-
tween genotype and phenotype. We focus on the genetic variation of
molecular traits and their dynamics (step 3) and on network modelling
and causal inference analysis (step 4) to illustrate how systems genetics
can provide the systems-wide view on disease aetiology that is urgently
needed for effective diagnosis and development of therapeutic
interventions.
2. Genetic variation of molecular traits
Genetic loci can enforce their risk via intermediate molecular traits,
such as gene expression, proteins and metabolites, resulting in inter-
individual variation of biomolecules that is under genetic control. Amo-
lecular trait can therefore be viewed as a quantitative trait and used in
genome-wide association studies in natural populations or linkage anal-
yses in segregating populations. By using these genetical genomics anal-
yses, the genomic locus underlying the variation in the measured trait,
called quantitative trait locus (QTL), can be identiﬁed [14]. The ﬁrst
genome-wide genetic analysis on gene expression was performed in
haploid yeast segregants [15] and this proof-of-concept analysis dem-
onstrated a widespread genetic effect on gene expression. Subsequent
studieswere carried out inmanydifferent organisms, including humans
[16–20], and on other molecular levels, such as proteins [21–23], me-
tabolites [24–26] and methylation [27,28]. These studies have greatly
increased our knowledge of the functional consequences of genetic
variants.p
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ssociation and genomics analyses to construct the causal inference from genotype to phe-
a (o) and phenotype data (p) and can be used to build a network and infer causality for the
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As transcripts are the ﬁrst direct products of DNA, deﬁning the ge-
netic variation on gene expression can provide crucial functional infor-
mation on genetic variation. The genomic loci that underlie variation in
gene expression are called expression quantitative trait loci (eQTL).
Based on the physical distance between the eQTL and the affected
gene, the eQTL can be classiﬁed as cis-eQTL or trans-eQTL. A cis-eQTL re-
fers to a SNP and a gene that are in the vicinity of each other (commonly
within a distance of 250 kb to 1 Mb in natural populations and 1–5 Mb
in segregating populations) [29,30], while trans-eQTLs are SNP-gene
pairs that are further away from each other or which may even lie on
different chromosomes. eQTL analysis can have different implications
for interpreting GWAS associations and constructing networks, for in-
stance cis-eQTLs can help to prioritize causal variants and candidate
genes at disease-associated loci. Over 40% of disease-associated SNPs
are observed to have a cis-acting effect on gene expression [31,32].
Based on this reasoning, the cis-eQTL has been successfully used to se-
lect the novel but weak associations that do not pass the genome-
wide signiﬁcance level in GWAS, thereby bypassing the need to increase
the sample size [33,34]. Another important potential advantage of
studying eQTLs is that they can provide insight into the disease mecha-
nism and underlying pathways. Trans-eQTLs can affect downstream
disease genes which were not identiﬁed by GWAS before and are be-
coming increasingly important to resolve themolecular pathways lead-
ing to disease [35]. However, a systematic identiﬁcation of trans-eQTLs
is challenging, as a trans-eQTL is believed to be an indirect association
and has a smaller effect than a cis-eQTL. Due to the robustness of biolog-
ical systems and the theory of phenotypic buffering, molecular factors
located further downstream in the pathway tend to have a smaller ef-
fect than the factors upstream [36]. Recent advances in the develop-
ment of statistical frameworks for trans-eQTL analysis [37] and the
dramatically increased sample size [38] now allow for a systematic
identiﬁcation of trans-eQTLs, providing insight into the downstream ef-
fects of trait-associated variants. A recent systematic trans-eQTL analysis
in 8086 human individuals has reported trans-effects for 233 disease-
associated SNPs [38]. One striking example is a SNP associatedwith sys-
temic lupus erythematosus (SLE). This SNP was found not only to affect
the expression of the transcription factor IKZF1 (IKAROS family zinc
ﬁnger) in cis, but it also affects the expression of 10 different genes in
trans, including four genes involved in the complement system and six
in type 1 interferon response. Both of these processes are important
for SLE. This study demonstrated the power of trans-eQTL analysis in
identifying key regulators of disease and their downstream effects.
2.2. Genetic effects can propagate to different molecular levels
Expression quantitative trait locus studies have proven to be power-
ful in functional genomics. But in order to gain a full picture of the dis-
ease process, it is important to study how genetic variation propagates
from DNA to transcripts and further to other ~omics levels, such as pro-
teins andmetabolites. The success of eQTL studies suggests that there is
a potential value in applying the QTL approach to other molecular traits
aswell. For example,Melzer et al. evaluated the role of genetic variation
on the levels of 42 proteinsmeasured in 1200 individuals [21]. They de-
tected cis-effects for eight proteins and trans-effects for one protein. Six
of these eight proteins correlatedwith inﬂammatory ormetabolic path-
ways and provided a mechanistic view on the disease process. On the
metabolism level, the most studied trait would be blood lipid levels
and up to date 157 loci have been robustly established [39,40]. These
loci account for ~10–20% of the variation in blood lipids and often un-
derlie susceptibility to many cardiovascular and metabolic traits. With
the developments in high-throughput technologies, like nuclear mag-
netic resonance (NMR) and mass spectrometry, an increasing number
of protein and metabolites can be quantiﬁed. This was demonstrated
by Karsten Suhre's group, who conducted a comprehensive andsystematic evaluation of genetic variance in blood metabolism. They
analysed over 250 metabolites in serum samples, thereby advancing
our knowledge of the molecular basis for many metabolic diseases
[25,41]. An example of a locus that was found to be associated with
blood metabolite concentrations is the FADS1 gene (fatty acid
desaturase 1). This locus is also associated with multiple complex dis-
eases and traits, including inﬂammatory bowel disease [42,43], heart
rate [44], insulin resistance and type 2 diabetes [45,46]. Genetic variants
in this gene were observed to have a modest effect on the expression of
FADS1 [38] as well as on blood HDL cholesterol, LDL cholesterol and tri-
glyceride levels [47]. Their strongest effect was seen on phospholipids,
explaining up to 40% of the observed variation for this trait [41]. This
ﬁnding suggests that investigating the genetic effect onmultiple molec-
ular levels can provide a system-wide view on the downstream effects
of disease-associated SNPs and subsequent mechanistic insights into
the disease aetiology.
3. Dynamics of genetic variation
Genetic variants are observed to have a dynamic effect, depending
on the cell-type, tissue-type, developmental stage or environmental
condition [48,49]. Several studies have estimated the proportion of cis-
regulated gene expression speciﬁc to certain cell-types [50–52] or tis-
sues [53–56]. Although most cis-eQTLs show a concordant association
across different samples, a substantial proportion exerts a speciﬁc effect.
For example, Ding et al. found a difference in cis-eQTLs of only 1–5%
when comparing psoriatic skin samples and healthy skin samples, but
a difference of 30% when they compared eQTLs between skin and
lymphoblastoid cell lines (LCLs) [56]. Similarly, 27.8% of the cis-eQTL
was found to be tissue-speciﬁc when comparing blood, liver, adipose
tissues and muscle [55], while 29% appeared to be tissue-speciﬁc in a
comparison study between LCLs, skin and fat tissue [54]. These discov-
eries have huge implications for disease studies, as they emphasize
the importance of using gene expression data from tissues relevant for
the disease under study. For instance, for type 2 diabetes (T2D), eQTL
studies have mainly been focusing on liver, adipose tissue, muscle and
pancreatic B cells, and it was shown that T2D-associated SNPs were
enriched for cis-eQTLs in liver and adipose tissue [34]. Not only cis-
eQTLs but also trans-eQTLs can exert cell-type or tissue-type speciﬁc ef-
fects. In a more recent study, T2D-associated SNPs were functionally
characterized through trans-eQTL analysis in ﬁve different tissue types
[57]. The authors found an enrichment of a tissue-speciﬁc trans-effect
for T2D SNPs. This suggested the downstream effect of T2D-associated
genetic variants and the underlying pathways that may be active in
the disease pathogenesis.
3.1. The role of the environment
Environmental factors also play an important role in shaping the ge-
netic effect. Cadwell et al. [58,59] demonstrated that the interaction of
genes and environment can determine disease phenotypes in the intes-
tine. In a mouse model they found that the combination of an environ-
mental trigger (a norovirus infection) and a genetic variant in the
ATG16L1 gene (a key gene involved in autophagy and previously associ-
ated with Crohn's disease) is required to generate the Paneth cell secre-
tory abnormalities characteristic of Crohn's disease in human. There is
also increasing evidence to indicate the important interplay between
the gutmicrobiota and host genetics in disease. Patientswith inﬂamma-
tory bowel disease (IBD) and risk alleles in the IBD susceptibility genes
NOD2 and ATG16L1 show altered intestinal microbiota compositions,
with signiﬁcant shifts in the frequencies of the Faecalibacterium
and Escherichia taxa [60]. Host genetics may therefore substantially
inﬂuence the structure and establishment of the gut microbiome [61].
Understanding the complex interactions between genetics and en-
vironmental factors would greatly beneﬁt from a systems genetics ap-
proach. An example of this is a study by Parks et al., who examined
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response to a high fat and sucrose diet [62]. Using a systems genetics ap-
proach, they combined GWAS and eQTL analyses with the systematic
proﬁling of obesity traits and gut microbiota composition to assess
gene–environment interactions, which would not have been possible
with classic linkage studies or GWAS alone. Their ﬁndings showed
that host genetics have a profound effect on shaping the plasticity of
the gut microbiota in response to an environmental trigger. These ex-
amples thus illustrate the importance and promise of integrating genet-
ic information with data from diverse multi-omics platforms towards
delineating and understanding disease biology.
3.2. Longitudinal studies
In order to determine the pathways and networks that are activated
during the onset and the development of diseases or during ageing, it
can be valuable to monitor biomolecular levels over time. Current
~omics proﬁling efforts usually capture a snapshot of a set of molecules
and their activity at deﬁned time points. In order to establish the causal
effects and their downstream events, it is important to also explore and
take into account the time-delay or phase lag in the analysis of disease
relations, such aswith time-series analysis [63]. One of theﬁrst compre-
hensive and very promising longitudinal multi-omics studies has been
the iPOP (integrative personal omics proﬁling) project led by Michael
Snyder [64]. In this study, data was integrated from genomic,
transcriptomic, proteomic, metabolomic and autoantibody proﬁles
sampled from a single healthy individual over a 14-month period.
First, the genome of the individual was sequenced and SNPs, indels
and structural variants were determined. Based on these outcomes
they assessed the genetic disease risk, revealing an elevated risk for cor-
onary artery disease, basal cell carcinoma, hypertriglyceridemia and
type 2 diabetes. Accordingly, next to the levels of transcripts, proteins
and metabolites, markers associated with high-risk disease phenotypes
were alsomonitored, such as glucose levels and HbA1c. One particularly
striking observation was that an elevated glucose response onset was
tightly associated with respiratory syncytial virus (RSV) infection. Al-
though not yet proven, this observation has led to the interesting hy-
pothesis that viral infections could perhaps trigger an altered glucose
metabolic response that predisposes an individual to type 2 diabetes.
4. Network modelling and causal inference
It is clear that the underlyingmechanisms of complex traits and dis-
eases have a complex basis, where the phenotype can be the result of
several genetic, molecular and environmental interactions. The next
step is to develop and apply user-friendly computational algorithms to
integrate and analyse the different phenotypic measurements and to
gain a clear picture of the biological complexity [65].
4.1. Network modelling
Network reconstruction is a powerful and widely used approach
that provides a ﬂexible framework on which the complexity associated
with biological pathways can be built systematically. A biological net-
work depicts molecules (or a collection of molecules organized into
functional modules) in a given biological system as nodes and their in-
teractions as edges between the nodes. The edges can represent any
type of relationship or association, such as regulation, physical binding,
correlation or dependency between nodes. The reconstructed networks
can incorporate curated information as well as data-driven relation-
ships and can be inferred using different algorithms, including linear
models, Bayesian approaches and equation-based methods [66,67].
Networkmodelling has been applied to a wide range of biological prob-
lems in the past few years, and has contributed to the discovery of sev-
eral disease genes and biomarkers [68–71]. For example, Bordbar et al.
used multi-omics data analysis (transcriptomics, proteomics andmetabolomics) to construct a genome-scale metabolic network, which
allowed them to determine metabolic modulators of macrophage acti-
vation [72]. Similarly, Tannahill and colleagues generated a metabolic
map of lipopolysaccharide (LPS)-activated macrophages by combining
metabolomic and transcriptomic data. They found that glycolytic
genes were induced and were also correlated with expression proﬁles
of the altered metabolites [73]. This led to the novel observation that
succinate is an important (but previously under-appreciated) metabo-
lite in innate immune signalling.
4.2. Inferring causality
When genetic information is incorporated into the network, it can
support the inference of causality for the interactions among different
traits. As genetic information ﬂows from DNA to the intermediate phe-
notypes and eventually to the ﬁnal phenotype (disease), there is a good
indication that the disease-associated gene is also the causal genewhen
both the intermediate phenotype and the disease phenotype are associ-
ated with the same genetic variant. For example, such a strategy helped
Musunuru and colleagues identify the SORT1 gene as the causal gene
underlying plasma LDL cholesterol and myocardial infarction [74]. By
integrating eQTL data and lipid level measurements they found a
liver-speciﬁc eQTL effect on the expression of the SORT1 gene, suggest-
ing a transcriptional regulatory role of the disease-associated SNP. The
association of the same SNP with plasma LDL cholesterol also pointed
towards a role in lipid processes. Functional analyses indeed conﬁrmed
the regulatory mechanism of modulating hepatic secretion of very low-
density lipoprotein (VLDL).
When a disease-associated SNP is also found to affect a molecular
trait, the causal relationship between the molecular phenotype and
the disease phenotype is not directly clear. Several models are possible
(Fig. 2): 1) the SNP can affect the molecular phenotype and the disease
phenotype independently (independentmodel); or 2) the SNP can alter
the molecular phenotype, which causes the development of disease
(causal model); or 3) the SNP can cause the disease and in response to
the disease status the molecular phenotype is changed (reactive
model). Thus, to systematically construct the molecular pathway from
genotype to phenotype, mathematical models and computational algo-
rithms are needed to distinguish between the different models [75].
For example, Schadt et al. developed a likelihood-based causality
model selection (LCMS) method for this [76]. In several succeeding
studies they demonstrated the use of their LCMSmodel to identify obe-
sity and atherosclerosis genes in mouse F2 populations [76–78].
Through the integration of DNA variation, gene expression and pheno-
typic information, the authors found that perturbations of predicted
obesity genes resulted in signiﬁcant changes in obesity-related traits
[78]. In the atherosclerosis study, the LCMS model was used with
mouse liver and adipose tissues, yielding hundreds of genes that tested
as causal for aortic lesions [77]. One of these candidate causal genes,
C3ar1, was experimentally validated using a mouse knockout model in
the same study. Several causal genes were also found to be enriched
for human cardiovascular disease-related SNPs identiﬁed by the
Wellcome Trust Case Control Consortium [79]. These studies clearly
demonstrate the effective use and power of statistical andmathematical
models to identify causal relationships for complex diseases.
5. Challenges and future perspectives
Several studies have demonstrated the power of systems genetics in
understanding disease aetiology. However, there are still major chal-
lenges to face and several considerations need to be taken into account
when designing a systems genetics experiment.
The ﬁrst challenge is the comprehensive acquisition of multi-
dimensional in-depth phenotype data. At the moment, for many dis-
eases, the data are scarce and heterogeneous in nature, making it difﬁ-
cult to study the dynamics of disease networks. Hence, the ideal
go p
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Fig. 2. Inference of causality.When two traits share a genetic association, statistical ormathematical models can be used to infer the relationship between the genotype (g), themolecular
trait, represented by ~omics proﬁling data (o), and the phenotype (p). An association can be reactive, causal or independent. The correlation between the residuals of the traits, after ac-
counting for genetic effects, can distinguish between the different causality models [76].
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the same individuals on multiple molecular levels and across different
conditions and tissue types. Obviously, the economics of generating
high-throughput data are an important factor here. Although the prices
for these technologies are dropping fast, they will need to decline fur-
ther in order to make longitudinal multi-omics studies readily afford-
able. It will be crucial for the years to come, to team up in consortia
and use and combine the data that is publicly available in biobanks
and databases. For instance, the Genotype-Tissue Expression (GTEx)
programme of the Broad Institute (www.broadinstitute.org/gtex/) [80]
aims to create a comprehensive public atlas of gene expression and reg-
ulation across multiple human tissues, and is a good ﬁrst step in this di-
rection. Likewise, in recent years, various prospective cohort studies
have been set up, in which a group of individuals is followed over
time, eventually making it possible to predict potential disease out-
comes based on genetic risk, molecular biomarkers, physiological traits,
and environmental factors [81-82, 69]. As demonstrated by the work of
Michael Snyder's group, monitoring the development of potential dis-
eases over time, combined with ~omics proﬁling, can provide a better
understanding of the mechanism leading to disease [64].
The second challenge is related to the ﬁrst and concerns the statisti-
cal power. In a systems genetics study, it is important to assess an ade-
quate number of samples to get enough power for association testing.
Although the sample size for GWAS and ~omics proﬁling has greatly in-
creased over the past ﬁve years to include several thousands of samples,
the number of samples can still be much lower than the number of fac-
tors tested at the genome-wide level (e.g., genetic factors or molecular
factors). The result will be that, at the stringent signiﬁcance level re-
quired to correct for multiple-testing, only the strong effects can be de-
tected and more modest effects will be missed. In order to detect the
more subtle effects, either the sample size needs to be increased dra-
matically or analysis approaches need to be applied to reduce the data
complexity. Network analysis can also be of help here, as it can be
used to cluster the separate factors intomodules based on their function
or their participation in a common biological process or pathway. Rath-
er than examining the effect of individual molecules, suchmodelling al-
lows one to examine the collective effect of groups of molecules,
providing increased power.
A third challenge is the complexity of the causal inference. As more
molecular phenotypes are measured, causative signals can be traced
up and down a biological network. If variation can be determined at sev-
eral of these phenotypic levels, then a proportion could be explained bythe same genetic variant. As mentioned earlier, various mathematical
models and algorithms can be used to characterize the relationships,
such as linear regression modelling or Mendelian randomization [83].
However, causal relationships are expected to be much more complex
than the models described in Fig. 2 [84]. Many confounding factors re-
main unknown or undetectable. As a result, more advanced mathemat-
ical models and algorithms have been proposed, including Bayesian
networks [85] and structural equation modelling [86]. New methods
need to be developed in the coming years that can take different as-
sumptions for different data-types into account.
For genomics data to contribute to our understanding of disease bi-
ology we must ﬁrst take the hurdle of integrating all the information
that is now being generated. As we have discussed in this review, sys-
tems genetics has proven to be a promising approach to achieve this.
In this respect, it is crucial to shift from the classical gene-centred
view of disease biology to a network perspective, in which system-
wide interactions inmultiple cell types, tissues, organs and the environ-
ment together deﬁne the disease state. As systems genetics has the po-
tential to generate these network-wide views on disease aetiology, it is
likely to become a major tool in the development of personalized med-
icine and disease prevention in the near future.
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